NEW YORK, June 19, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Compass Group Diversified Holdings, LLC ("Compass Diversified" or the "Company") (NYSE: CODI) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Compass Diversified investors who were adversely affected by alleged securities fraud between May 1, 2024 and May 7, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.co ...

Core Viewpoint - GeneDx Holdings Corp. is under investigation for potential violations of federal securities laws and unlawful business practices, following allegations of widespread fraud and revenue inflation tactics [1][2]. Group 1: Allegations and Investigations - Grizzly Research published a report claiming that GeneDx's growth is largely an illusion, driven by fraudulent schemes aimed at exploiting Medicaid and Medicare systems to inflate revenue [2]. - The report alleges that GeneDx has engaged in "code stacking," allowing the company to bill insurance providers for services that do not meet required criteria [2]. - Testimonies from former employees and ongoing litigation suggest that the company's executives, including CEO Katherine Stueland and CFO Kevin Feeley, have sold shares immediately upon vesting, indicating potential insider knowledge of imminent risks [2]. Group 2: Market Reaction - Following the release of the Grizzly report, GeneDx's stock price fell by $4.84 per share, or 6.72%, closing at $67.18 per share on February 5, 2025 [2]. Group 3: Legal Representation - Bragar Eagel & Squire, P.C. is representing GeneDx stockholders in the investigation and is seeking information from those who have suffered losses or have relevant information regarding the claims [1][3].

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to the safety and clinical trial protocol of its RP-A501 treatment, which resulted in a significant stock price decline after the FDA placed a clinical hold on the study [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors affected by alleged securities fraud between February 27, 2025, and May 26, 2025 [1]. - Defendants allegedly made positive statements while concealing material adverse facts about RP-A501's safety, including the risk of Serious Adverse Events (SAEs) [2]. - Following the announcement of a clinical hold by the FDA due to a SAE, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025, marking a decline of approximately 37% in one trading day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until August 11, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Fortrea Holdings Inc. ("Fortrea Holdings Inc." or the "Company") (NASDAQ: FTRE) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Fortrea Holdings Inc. investors who were adversely affected by alleged securities fraud between July 3, 2023 and February 28, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/psl ...

Core Viewpoint - A class action securities lawsuit has been filed against Ibotta, Inc. due to alleged securities fraud related to its initial public offering on April 18, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who purchased Ibotta securities and were negatively impacted by the alleged fraud [2]. - The complaint alleges that Ibotta failed to disclose the risks associated with its contract with The Kroger Co., specifically that the contract was at-will, allowing Kroger to terminate it without notice [3]. - Ibotta provided detailed information about its contract with Walmart but did not mention the at-will nature of the Kroger contract, misleading investors about the stability of its client relationships [3]. Group 2: Next Steps for Investors - Investors who suffered losses in Ibotta have until June 16, 2025, to request to be appointed as lead plaintiff in the lawsuit [4]. - Participation in the lawsuit does not require any out-of-pocket costs for class members, and they may be entitled to compensation [4]. Group 3: Law Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [5]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [5].

Core Viewpoint - A lawsuit has been filed against Organon & Co. and certain senior executives for potential violations of federal securities laws, particularly related to misleading statements about the company's dividend policy following a significant acquisition [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of New Jersey, captioned Hauser v. Organon & Co., et al., No. 25-cv-05322, and claims are made under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [2]. - Investors have until July 22, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background and Acquisition - Organon is a global healthcare company focused on women's health and has historically provided a healthy dividend to its shareholders [3]. - In October 2024, Organon completed a $1.2 billion acquisition of Dermavant, a biopharmaceutical company, which increased the company's debt [3]. Group 3: Dividend Policy and Stock Performance - Following the acquisition, Organon assured investors it would maintain its dividend, claiming it was the "1 capital allocation priority," but later shifted focus to debt reduction, leading to a severe cut in its dividend [3]. - On May 1, 2025, Organon announced a reduction in its dividend payout from $0.28 per share to $0.02 per share, resulting in a stock price decline of approximately 27%, from $12.93 on April 30, 2025, to $9.45 on May 1, 2025 [4].

NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Compass Diversified Holdings and Compass Group Diversified Holdings, LLC (NYSE: CODI) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Compass you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/compass-diversified-holdings. Investors ...

A lawsuit was filed in the United States District Court for the Eastern District of New York on behalf of investors who purchased or acquired the securities of PepGen between March 7, 2024 and March 3, 2025, inclusive, alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its senior officers. NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds PepGen Inc. ("PepGen" or the "Company") (NASDAQ: PEPG ...

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Open Lending Corporation ("Open Lending Corporation" or the "Company") (NASDAQ: LPRO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Open Lending Corporation investors who were adversely affected by alleged securities fraud between February 24, 2022 and March 31, 2025. Follow the link below to get more information and be contacted by a member of our team: https:// ...

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in PepGen Inc. ("PepGen Inc." or the "Company") (NASDAQ: PEPG) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of PepGen Inc. investors who were adversely affected by alleged securities fraud between March 7, 2024 and March 3, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/pepgen-inc-lawsuit-submissio ...